ABION Inc. (KOSDAQ:203400)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,155.00
-45.00 (-1.41%)
At close: Feb 27, 2026
-6.60%
Market Cap 284.27B
Revenue (ttm) 1.03B
Net Income (ttm) -28.06B
Shares Out 90.10M
EPS (ttm) -553.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,414,743
Average Volume 1,576,906
Open 3,225.00
Previous Close 3,200.00
Day's Range 3,145.00 - 3,315.00
52-Week Range 1,911.11 - 7,277.78
Beta 1.14
RSI 37.31
Earnings Date Mar 20, 2026

About ABION

ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various re... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2007
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 203400
Full Company Profile

Financial Performance

In 2024, ABION's revenue was 759.68 million, a decrease of -40.38% compared to the previous year's 1.27 billion. Losses were -43.38 billion, 48.5% more than in 2023.

Financial Statements

News

There is no news available yet.